Human cytomegalovirus promotes survival of infected monocytes via a distinct temporal regulation of cellular Bcl-2 family proteins

Journal of Virology

Volumn 90, Issue 5, 2016, Pages 2356-2371

  Collins McMillen, Donna ^a,b   Kim, Jung Heon ^a,b   Nogalski, Maciej T ^a,c   Stevenson, Emily V ^a,b   Chan, Gary C ^a,d   Caskey, Joshua R ^a   Cieply, Stephen J ^a,b   Yurochko, Andrew D ^a,b  

^a LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b Louisiana State University Health Sciences Center at Shreveport   (United States)

^c PRINCETON UNIVERSITY   (United States)

^d State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; EPIDERMAL GROWTH FACTOR RECEPTOR; INTEGRIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN MCL 1; PROTEIN TYROSINE KINASE; SMALL INTERFERING RNA; VENETOCLAX; BAX PROTEIN, HUMAN;

ARTICLE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME ACTIVATION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; MONOCYTE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; VIRUS ATTACHMENT; BIOSYNTHESIS; CELL CULTURE; CYTOMEGALOVIRUS; HOST PATHOGEN INTERACTION; METABOLISM; PHYSIOLOGY; VIROLOGY;

BCL-2-ASSOCIATED X PROTEIN; CELL SURVIVAL; CELLS, CULTURED; CYTOMEGALOVIRUS; HOST-PATHOGEN INTERACTIONS; HUMANS; MONOCYTES; PROTO-ONCOGENE PROTEINS C-BCL-2; UP-REGULATION;

EID: 84961172486     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01994-15     Document Type: Article

References (92)

1. Mocarski E, Jr, Shenk T, Griffiths PD, Pass R. 2013. Cytomegaloviruses, p 1960-2014. In Knipe DM, Howley PM (ed), Fields virology, vol 2. Lippincott Williams & Wilkins, Philadelphia, PA.
2. Nogalski MT, Collins-McMillen D, Yurochko AD. 2014. Overview of human cytomegalovirus pathogenesis, p 15-28. In Yurochko AD, Miller WE (ed), Human cytomegaloviruses: methods & protocols. Humana Press, New York, NY.
3. Cohen JI, Corey GR. 1985. Cytomegalovirus infection in the normal host. Medicine 64:100-114.
4. Wreghitt TG, Teare EL, Sule O, Devi R, Rice P. 2003. Cytomegalovirus infection in immunocompetent patients. Clin Infect Dis 37:1603-1606. http://dx.doi.org/10.1086/379711.
5. Speir E, Modali R, Huang ES, Leon MB, Shawl F, Finkel T, Epstein SE. 1994. Potential role of human cytomegalovirus and p53 interaction in coronary restenosis. Science 265:391-394. http://dx.doi.org/10.1126/science.8023160.
6. Melnick JL, Adam E, DeBakey ME. 1995. Cytomegalovirus and atherosclerosis. Bioessays 17:899-903. http://dx.doi.org/10.1002/bies.950171012.
7. Waldman WJ, Adams PW, Knight DA, Sedmak DD. 1997. CMV as an exacerbating agent in transplant vascular sclerosis: potential immunemediated mechanisms modelled in vitro. Transplant Proc 29:1545-1546. http://dx.doi.org/10.1016/S0041-1345(96)00670-7.
8. Streblow DN, Orloff SL, Nelson JA. 2001. Do pathogens accelerate atherosclerosis? J Nutr 131:2798S-2804S.
9. Streblow DN, Vomaske J, Smith P, Melnychuk R, Hall L, Pancheva D, Smit M, Casarosa P, Schlaepfer DD, Nelson JA. 2003. Human cytomegalovirus chemokine receptor US28-induced smooth muscle cell migration is mediated by focal adhesion kinases and Src. J Biol Chem 278:50456-50465. http://dx.doi.org/10.1074/jbc.M307936200.
10. Geder L, Sanford EJ, Rohner TJ, Rapp F. 1977. Cytomegalovirus and cancer of the prostate: in vitro transformation of human cells. Cancer Treat Rep 61:139-146.
11. Cobbs CS, Harkins L, Samanta M, Gillespie GY, Bharara S, King PH, Nabors LB, Cobbs CG, Britt WJ. 2002. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res 62:3347-3350.
12. Harkins L, Volk AL, Samanta M, Mikolaenko I, Britt WJ, Bland KI, Cobbs CS. 2002. Specific localisation of human cytomegalovirus nucleic acids and proteins in human colorectal cancer. Lancet 360:1557-1563. http://dx.doi.org/10.1016/S0140-6736(02)11524-8.
13. Rapp F, Robbins D. 1984. Cytomegalovirus and human cancer. Birth Defects Orig Artic Ser 20:175-192.
14. Shen CY, Ho MS, Chang SF, Yen MS, Ng HT, Huang ES, Wu CW. 1993. High rate of concurrent genital infections with human cytomegalovirus and human papillomaviruses in cervical cancer patients. J Infect Dis 168: 449-452. http://dx.doi.org/10.1093/infdis/168.2.449.
15. Hsieh CY, You SL, Kao CL, Chen CJ. 1999. Reproductive and infectious risk factors for invasive cervical cancer in Taiwan. Anticancer Res 19: 4495-4500.
16. Klatt EC, Shibata D. 1988. Cytomegalovirus infection in the acquired immunodeficiency syndrome. Clinical and autopsy findings. Arch Pathol Lab Med 112:540-544.
17. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE. 1992. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis 166:1223-1227.
18. Bowen EF, Wilson P, Cope A, Sabin C, Griffiths P, Davey C, Johnson M, Emery V. 1996. Cytomegalovirus retinitis in AIDS patients: influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival. AIDS 10:1515-1520. http://dx.doi.org/10.1097/00002030-199611000-00009.
19. Selik RM, Chu SY, Ward JW. 1995. Trends in infectious diseases and cancers among persons dying of HIV infection in the United States from 1987 to 1992. Ann Intern Med 123:933-936. http://dx.doi.org/10.7326/0003-4819-123-12-199512150-00006.
20. Spector SA, Hsia K, Crager M, Pilcher M, Cabral S, Stempien MJ. 1999. Cytomegalovirus (CMV) DNA load is an independent predictor of CMV disease and survival in advanced AIDS. J Virol 73:7027-7030.
21. Rifkind D. 1965. Cytomegalovirus infection after renal transplantation. Arch Intern Med 116:554-558.
22. Myers JD, Spencer HCJ, Watts JC, Gregg MB, Stewart JA, Troupin RH, Thomas ED. 1975. Cytomegalovirus pneumonia after human marrow transplantation. Ann Intern Med 82:181-188. http://dx.doi.org/10.7326/0003-4819-82-2-181.
23. Ho MS. 1977. Virus infections after transplantation in man. Brief review. Arch Virol 55:1-24. http://dx.doi.org/10.1007/BF01314475.
24. Rubin RH, Russell PS, Levin M, Cohen C. 1979. From the National Institutes of Health. Summary of a workshop on cytomegalovirus infections during organ transplantation. J Infect Dis 139:728-734.
25. Winston DJ, Gale RP, Meyer DV, Young LS. 1979. Infectious complications of human bone marrow transplantation. Medicine 58:1-31. http://dx.doi.org/10.1097/00005792-197901000-00001.
26. Rubin RH. 1990. Impact of cytomegalovirus infection on organ transplant recipients. Rev Infect Dis 12(Suppl 7):S754-S766. http://dx.doi.org/10.1093/clinids/12.Supplement_7.S754.
27. Rubin RH. 2002. Clinical approach to infection in the compromised host, p 573-679. In Young LS, Van Furth R (ed), Infection in the organ transplant recipient. Kluwer Academic Press, New York, NY.
28. Rubin RH, Wolfson JS, Cosimi AB, Tolkoff-Rubin NE. 1981. Infection in the renal transplant recipient. Am J Med 70:405-411. http://dx.doi.org/10.1016/0002-9343(81)90780-4.
29. Hanshaw JB. 1971. Congenital cytomegalovirus infection: a fifteen year perspective. J Infect Dis 123:555-561. http://dx.doi.org/10.1093/infdis/123.5.555.
30. Stagno S, Reynolds DW, Amos CS, Dahle AJ, McCollister FP, Mohindra I, Ermocilla R, Alford CA. 1977. Auditory and visual defects resulting from symptomatic and subclinical congenital cytomegaloviral and toxoplasma infections. Pediatrics 59:669-678.
31. Pass RF, Stagno S, Myers GJ, Alford CA. 1980. Outcome of symptomatic congenital cytomegalovirus infection: results of long-term longitudinal follow-up. Pediatrics 66:758-762.
32. Williamson WD, Desmond MM, LaFevers N, Taber LH, Catlin FI, Weaver TG. 1982. Symptomatic congenital cytomegalovirus. Disorders of language, learning, and hearing. Am J Dis Child 136:902-905.
33. Bale JFJ. 1984. Human cytomegalovirus infection and disorders of the nervous system. Arch Neurol 41:310-320. http://dx.doi.org/10.1001/archneur.1984.04050150092023.
34. Fowler KB, Stagno S, Pass RF, Britt WJ, Boll TJ, Alford CA. 1992. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med 326:663-667. http://dx.doi.org/10.1056/NEJM199203053261003.
35. Bissinger AL, Sinzger C, Kaiserling E, Jahn G. 2002. Human cytomegalovirus as a direct pathogen: correlation of multiorgan involvement and cell distribution with clinical and pathological findings in a case of congenital inclusion disease. J Med Virol 67:200-206. http://dx.doi.org/10.1002/jmv.2208.
36. Yurochko AD. 2008. Human cytomegalovirus modulation of signal transduction. Curr Top Microbiol Immunol 325:205-220.
37. Sinclair J, Sissons P. 1996. Latent and persistent infections of monocytes and macrophages. Intervirology 39:293-301.
38. Sinzger C, Jahn G. 1996. Human cytomegalovirus cell tropism and pathogenesis. Intervirology 39:302-319.
39. Taylor-Wiedeman J, Sissons P, Sinclair J. 1994. Induction of endogenous human cytomegalovirus gene expression after differentiation of monocytes from healthy carriers. J Virol 68:1597-1604.
40. Pulliam L. 1991. Cytomegalovirus preferentially infects a monocyte derived macrophage/microglial cell in human brain cultures: neuropathology differs between strains. J Neuropathol Exp Neurol 50:432-440. http://dx.doi.org/10.1097/00005072-199107000-00004.
41. Booss J, Dann PR, Griffith BP, Kim JH. 1989. Host defense response to cytomegalovirus in the central nervous system. Predominance of the monocyte. Am J Pathol 134:71-78.
42. Smith MS, Bentz GL, Alexander JS, Yurochko AD. 2004. Human cytomegalovirus induces monocyte differentiation and migration as a strategy for dissemination and persistence. J Virol 78:4444-4453. http://dx.doi.org/10.1128/JVI.78.9.4444-4453.2004.
43. Smith MS, Bentz GL, Smith PM, Bivens ER, Yurochko AD. 2004. HCMV activates PI(3)K in monocytes and promotes monocyte motility and transendothelial migration in a PI(3)K-dependent manner. J Leukoc Biol 76:65-76. http://dx.doi.org/10.1189/jlb.1203621.
44. Smith MS, Bivens-Smith ER, Tilley AM, Bentz GL, Chan G, Minard J, Yurochko AD. 2007. Roles of phosphatidylinositol 3-kinase and NFkappaB in human cytomegalovirus-mediated monocyte diapedesis and adhesion: strategy for viral persistence. J Virol 81:7683-7694. http://dx.doi.org/10.1128/JVI.02839-06.
45. Chan G, Nogalski MT, Stevenson EV, Yurochko AD. 2012. Human cytomegalovirus induction of a unique signalsome during viral entry into monocytes mediates distinct functional changes: a strategy for viral dissemination. J Leukoc Biol 92:743-752. http://dx.doi.org/10.1189/jlb.0112040.
46. Yurochko AD, Huang ES. 1999. Human cytomegalovirus binding to human monocytes induces immunoregulatory gene expression. J Immunol 162:4806-4816.
47. Chan GCT, Nogalski MT, Yurochko AD. 2012. Human cytomegalovirus stimulates monocyte-to-macrophage differentiation via the temporal regulation of caspase 3. J Virol 86:10714-10723. http://dx.doi.org/10.1128/JVI.07129-11.
48. Stevenson EV, Collins-McMillen D, Kim JH, Cieply SJ, Bentz GL, Yurochko AD. 2014. HCMV reprogramming of infected monocyte survival and differentiation: a Goldilocks phenomenon. Viruses 6:782-807. http://dx.doi.org/10.3390/v6020782.
49. Chan GCT, Nogalski MT, Bentz GL, Smith MS, Parmater A, Yurochko AD. 2010. PI3K-dependent upregulation of Mcl-1 by human cytomegalovirus is mediated by epidermal growth factor receptor and inhibits apoptosis in short-lived monocytes. J Immunol 184:3213-3222. http://dx.doi.org/10.4049/jimmunol.0903025.
50. Whitelaw DM. 1972. Observations on human monocyte kinetics after pulse labeling. Cell Tissue Kinet 5:311-317.
51. Hume DA, Ross IL, Himes SR, Sasmono RT, Wells CA, Ravasi T. 2002. The mononuclear phagocyte system revisited. J Leukoc Biol 72:621-627.
52. Goldmacher VS. 2005. Cell death suppression by cytomegaloviruses. Apoptosis 10:251-265. http://dx.doi.org/10.1007/s10495-005-0800-z.
53. Fliss PM, Brune W. 2012. Prevention of cellular suicide by cytomegaloviruses. Viruses 4:1928-1949. http://dx.doi.org/10.3390/v4101928.
54. Goldmacher VS. 2004. Cell death suppressors encoded by cytomegalovirus. Prog Mol Subcell Biol 36:1-18. http://dx.doi.org/10.1007/978-3-540-74264-7_1.
55. Chan GCT, Nogalski MT, Yurochko AD. 2009. Activation of EGFR on monocytes is required for human cytomegalovirus entry and mediates cellular motility. Proc Natl Acad SciUSA106:22369-22374. http://dx.doi.org/10.1073/pnas.0908787106.
56. Nogalski MT, Chan G, Stevenson EV, Gray S, Yurochko AD. 2011. Human cytomegalovirus-regulated paxillin in monocytes links cellular pathogenic motility to the process of viral entry. J Virol 85:1360-1369. http://dx.doi.org/10.1128/JVI.02090-10.
57. Nogalski MT, Chan GCT, Stevenson EV, Collins-McMillen D, Yurochko AD. 2013. TheHCMVgH/gL/UL128-131 complex triggers the specific cellular activation required for efficient viral internalization into target monocytes. PLoS Pathog 9:e1003463. http://dx.doi.org/10.1371/journal.ppat.1003463.
58. Barber GN. 2001. Host defense, viruses and apoptosis. Cell Death Differ 8:113-126. http://dx.doi.org/10.1038/sj.cdd.4400823.
59. Upton JW, Chan FK. 2014. Staying alive: cell death in antiviral immunity. Mol Cell 54:273-280. http://dx.doi.org/10.1016/j.molcel.2014.01.027.
60. Bentz GL, Jarquin-Pardo M, Chan GCT, Smith MS, Sinzger C, Yurochko AD. 2006. Human cytomegalovirus (HCMV) infection of endothelial cells promotes naive monocyte extravasation and transfer of productive virus to enhance hematogenous dissemination of HCMV. J Virol 80: 11539-11555. http://dx.doi.org/10.1128/JVI.01016-06.
61. Bentz GL, Yurochko AD. 2008. Human CMV infection of endothelial cells induces an angiogenic response through viral binding to EGF receptor and beta1 beta3 integrins. Proc Natl Acad Sci U S A 105:5531-5536. http://dx.doi.org/10.1073/pnas.0800037105.
62. Chan GCT, Bivens-Smith ER, Smith MS, Smith PM, Yurochko AD. 2008. Transcriptome analysis reveals human cytomegalovirus reprograms monocyte differentiation toward an M1 macrophage. J Immunol 181: 698-711. http://dx.doi.org/10.4049/jimmunol.181.1.698.
63. Chan GCT, Bivens-Smith ER, Smith MS, Yurochko AD. 2009. NFkappaB and phosphatidylinositol 3-kinase activity mediates the HCMVinduced atypical M1/M2 polarization of monocytes. Virus Res 144:329-333. http://dx.doi.org/10.1016/j.virusres.2009.04.026.
64. DeMeritt IB, Milford LE, Yurochko AD. 2004. Activation of the NFkappaB pathway in human cytomegalovirus-infected cells is necessary for efficient transactivation of the major immediate-early promoter. J Virol 78:4498-4507. http://dx.doi.org/10.1128/JVI.78.9.4498-4507.2004.
65. DeMeritt IB, Podduturi JP, Tilley AM, Nogalski MT, Yurochko AD. 2006. Prolonged activation of NF-kappaB by human cytomegalovirus promotes efficient viral replication and late gene expression. Virology 346: 15-31. http://dx.doi.org/10.1016/j.virol.2005.09.065.
66. Nogalski MT, Podduturi JP, DeMeritt IB, Milford LE, Yurochko AD. 2007. The human cytomegalovirus virion possesses an activated casein kinase II that allows for the rapid phosphorylation of the inhibitor of NF-κB, IκBα. J Virol 81:5305-5314. http://dx.doi.org/10.1128/JVI.02382-06.
67. Wang D, Shenk T. 2005. Human cytomegalovirus UL131 open reading frame is required for epithelial cell tropism. J Virol 79:10330-10338. http://dx.doi.org/10.1128/JVI.79.16.10330-10338.2005.
68. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH. 2005. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677-681. http://dx.doi.org/10.1038/nature03579.
69. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, Willis SN, Scott CL, Day CL, Cory S, Adams JM, Roberts AW, Huang DCS. 2006. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10:389-399. http://dx.doi.org/10.1016/j.ccr.2006.08.027.
70. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ, Huang DCS, Hymowitz SG, Jin S, Khaw SL, Kovar PJ, Lam LT, Lee J, Maecker HL, Marsh KC, Mason KD, Mitten MJ, Nimmer PM, Oleksijew A, Park CH, Park C, Phillips DC, Roberts AW, Sampath D, Seymour JF, Smith ML, Sullivan GM, Tahir SK, Tse C, Wendt MD, Xiao Y, Xue JC, Zhang H, Humerickhouse RA, Rosenberg SH, Elmore SW. 2013. ABT-199, a potent and selective Bcl-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202-210. http://dx.doi.org/10.1038/nm.3048.
71. Ola MS, Nawaz M, Ahsan H. 2011. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis. Mol Cell Biochem 351:41-58. http://dx.doi.org/10.1007/s11010-010-0709-x.
72. Shalini S, Dorstyn L, Dawar S, Kumar S. 2015. Old, new and emerging functions of caspases. Cell Death Differ 22:526-539. http://dx.doi.org/10.1038/cdd.2014.216.
73. Han Z, Hendrickson EA, Bremner TA, Wyche JH. 1997. A sequential two-step mechanism for the production of the mature p17:p12 form of caspase-3 in vitro. J Biol Chem 272:13432-13436. http://dx.doi.org/10.1074/jbc.272.20.13432.
74. Sordet O, Rebe C, Plenchette S, Zermati Y, Hermine O, Vainchenker W, Garrido C, Solary E, Dubrez-Daloz L. 2002. Specific involvement of caspases in the differentiation of monocytes into macrophages. Blood 100: 4446-4453. http://dx.doi.org/10.1182/blood-2002-06-1778.
75. Adams JM, Cory S. 1998. The Bcl-2 protein family: arbiters of cell survival. Science 281:1322-1326. http://dx.doi.org/10.1126/science.281.5381.1322.
76. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. 2010. The Bcl-2 family reunion. Mol Cell 37:299-310. http://dx.doi.org/10.1016/j.molcel.2010.01.025.
77. Zhou P, Qian L, Kozopas KM, Craig RW. 1997. Mcl-1, a Bcl-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood 89:630-643.
78. Aichberger KJ, Mayerhofer M, Krauth MT, Skvara H, Florian S, Sonneck K, Akgul C, Derdak S, Pickl WF, Wacheck V, Selzer E, Monia BP, Moriggl R, Valent P, Sillaber C. 2005. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides. Blood 105:3303-3311. http://dx.doi.org/10.1182/blood-2004-02-0749.
79. Derenne S, Monia BP, Dean NM, Taylor JK, Rapp MJ, Harousseau JL, Bataille R, Amiot M. 2002. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 100:194-199. http://dx.doi.org/10.1182/blood.V100.1.194.
80. Glaser SP, Lee EF, Trounson E, Bouillet P, Wei A, Fairlie WD, Izon DJ, Zuber J, Rappaport AR, Herold MJ, Alexander WS, Lowe SW, Robb L, Strasser A. 2012. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev 26:120-125. http://dx.doi.org/10.1101/gad.182980.111.
81. Goodwin CM, Rossanese OW, Olejniczak ET, Fesik SW. 5 June 2015. Myeloid cell leukemia-1is an important apoptotic survival factor in triplenegative breast cancer. Cell Death Differ http://dx.doi.org/10.1038/cdd.2015.73.
82. Lee WS, Park YL, Kim N, Oh HH, Son DJ, Kim MY, Oak CY, Chung CY, Park HC, Kim JS, Myung DS, Cho SB, Joo YE. 2015. Myeloid cell leukemia-1 regulates the cell growth and predicts prognosis in gastric cancer. Int J Oncol 46:2154-2162.
83. Lee WS, Park YL, Kim N, Oh HH, Son DJ, Kim MY, Oak CY, Park HC, Kim JS, Myung DS, Cho SB, Kim HS, Joo YE. 2015. Myeloid cell leukemia-1 is associated with tumor progression by inhibiting apoptosis and enhancing angiogenesis in colorectal cancer. Am J Cancer Res 5:101-113.
84. Nalluri S, Pierce SK, Tanos R, Abdella HA, Karmali D, Hogarty MD, Goldsmith KC. 2015. EGFR signaling defines Mcl-1 survival dependency in neuroblastoma. Cancer Biol Ther 16:276-286. http://dx.doi.org/10.1080/15384047.2014.1002333.
85. Song L, Coppola D, Livingston S, Cress D, Haura EB. 2005. Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biol Ther 4:267-276. http://dx.doi.org/10.4161/cbt.4.3.1496.
86. Grabow S, Delbridge AR, Valente LJ, Strasser A. 2014. MCL-1 but not BCL-XL is critical for the development and sustained expansion of thymic lymphoma in p53-deficient mice. Blood 124:3939-3946. http://dx.doi.org/10.1182/blood-2014-09-601567.
87. Kozopas KM, Yang T, Buchan HL, Zhou P, Craig RW. 1993. Mcl-1, a gene expressed in programmed myeloid cell differentation, has sequence similarity to Bcl-2. Proc Natl Acad Sci U S A 90:3516-3520. http://dx.doi.org/10.1073/pnas.90.8.3516.
88. Yang T, Buchan HL, Townsend KJ, Craig RW. 1996. Mcl-1, a member of the Bcl-2 family, is induced rapidly in response to signals for cell differentiation or death, but not to signals for cell proliferation. J Cell Physiol 166:523-536. http://dx.doi.org/10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R.
89. Kobayashi S, Werneburg NW, Bronk SF, Kaufmann SH, Gores GJ. 2005. Interleukin-6 contributes to Mcl-1 up-regulation and TRAIL resistance via an Akt-signaling pathway in cholangiocarcinoma cells. Gastroenterology 128:2054-2065. http://dx.doi.org/10.1053/j.gastro.2005.03.010.
90. Hussain SR, Cheney CM, Johnson AJ, Lin TS, Grever MR, Caligiuri MA, Lucas DM, Byrd JC. 2007. Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clin Cancer Res 13:2144-2150. http://dx.doi.org/10.1158/1078-0432.CCR-06-2294.
91. Michels J, Obrist F, Vitale I, Lissa D, Garcia P, Behnam-Motlagh P, Kohno K, Wu GS, Brenner C, Castedo M, Kroemer G. 2014. Mcl-1 dependency of cicplatin-resistant cancer cells. Biochem Pharmacol 92:55-61. http://dx.doi.org/10.1016/j.bcp.2014.07.029.
92. Kumakura S, Ishikura H, Tsumura H, Nakashima A, Sato Y, Kobayashi S. 2000. Cell cycle-independent down-regulation of Bcl-2 protein expression in differentiating HL-60 cells. Leuk Lymphoma 36:375-382. http://dx.doi.org/10.3109/10428190009148859.